Connect your AI

ANI Pharmaceuticals ANIP Accrued consideration for acquired product rights and intangible assets

Other financials

Income statement

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

Market cap$1.88B+18.3%

Enterprise value$1.87B+5.8%

P/E20.4×—

P/S2×-0.3×

Profitability

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept anip:NoncashOrPartNoncashAcquisitionConsiderationAccrued.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's accrued consideration for acquired product rights and intangible assets.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ANI Pharmaceuticals's accrued consideration for acquired product rights and intangible assets?: ANI Pharmaceuticals (ANIP) reported accrued consideration for acquired product rights and intangible assets of $1.09M in Q1 2026.